357P Bridging the gap between real-world studies (RWSs) and randomized controlled trials (RCTs) of 1st-line palbociclib+aromatase inhibitors (P+AI) in hormone receptor-positive (HR+)/HER2-negative(-) metastatic breast cancer (mBC)S. Nucera, Daniele Generali, Massimo Milani et al.|Annals of Oncology|2024Cited by 0
371P Palbociclib plus endocrine therapy in clinically relevant HR+/HER2- mBC subgroups: A real-world multicenter studyR. Buonaiuto, C. De Angelis, R. Esposito et al.|ESMO Open|2025Cited by 0